<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04800250</url>
  </required_header>
  <id_info>
    <org_study_id>20-PP-26</org_study_id>
    <nct_id>NCT04800250</nct_id>
  </id_info>
  <brief_title>Treatment of Multiple Gingival Recession Defects Using a New Xenogenic Collagen Membrane Compared to Connective Tissue Graft: a Randomized Controlled Split-mouth Clinical Study</brief_title>
  <acronym>Mucogreffe</acronym>
  <official_title>Mucogain Matrix Versus Connective Tissue Graft: &quot;MUCOGREFFE Project&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Limitation of donor site and significant postoperative morbidity are often described in&#xD;
      connective tissue graft. We want to show if mucogain matrix used in tunnel technique to&#xD;
      recover RTI Cairo recessions defects could be an alternative to connective tissue graft&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Case-control</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean root coverage obtained with both techniques</measure>
    <time_frame>6 months</time_frame>
    <description>To compare the mean root coverage obtained with the Creos® Mucogain matrix and connective tissue graft in the treatment of Cairo RT1 class maxillary recessions (Miller Class 1).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain with both techniques</measure>
    <time_frame>6 months</time_frame>
    <description>To compare postoperative pain with both techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications with both techniques</measure>
    <time_frame>10 days</time_frame>
    <description>To compare the occurrence of postoperative complications (haemorrhage, edema) within the first 10 days.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Gingival Recession</condition>
  <arm_group>
    <arm_group_label>A - Mucogain matrix on right</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient will receive mucogain matrix on right side and connective tissue graft on left side.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B - Mucogain matrix on left</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient will receive mucogain matrix on left side and connective tissue graft on right side.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Treatment of gingival recessions</intervention_name>
    <description>Patients will have a surgery for their gingival recessions. They will be enrolled in the split mouth-study. They will have on one side mucogain matrix transplant, an on another side they will have the gold standard procedure</description>
    <arm_group_label>A - Mucogain matrix on right</arm_group_label>
    <arm_group_label>B - Mucogain matrix on left</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Patient with 3 contiguous, symmetrical and bilateral RTI Cairo gingival recessions&#xD;
             (Miller Class 1) (i.e. 6 recessions)&#xD;
&#xD;
          -  Patient non-smoker&#xD;
&#xD;
          -  Patient affiliated to social security&#xD;
&#xD;
          -  Patient signed informed consent.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Patient with or having presented an acute or chronic severe cardiovascular, kidney,&#xD;
             liver, gastrointestinal, allergic, endocrine, neuropsychiatric pathology, developed&#xD;
             cancer of the upper aero digestive tract treated with radiotherapy&#xD;
&#xD;
          -  Patient with severe hemorrhinopathy&#xD;
&#xD;
          -  Patient treated with oral retinoids, bisphosphonates, oral or anticonvulsants&#xD;
&#xD;
          -  Patient who has taken steroidal or non-steroidal anti-inflammatory therapy,&#xD;
             anti-cancer or immunosuppressive chemotherapy within the last 6 months.&#xD;
&#xD;
          -  Patient with contraindication to necessary and pre-, per- or post-operative treatments&#xD;
&#xD;
          -  Follow-up of the patient seemed difficult by the investigator&#xD;
&#xD;
          -  Patient with insufficient oral hygiene incompatible with oral surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laetitia I Imbert de la Phalecque</last_name>
    <phone>0492034819</phone>
    <email>imbertdelaphalecque.l@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital of Nice</name>
      <address>
        <city>Nice</city>
        <zip>06001</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laetitia Imbert de la Phalecque</last_name>
      <phone>0492034819</phone>
      <email>imbertdelaphalecque.l@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Séverine VINCENT-BUGNAS, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 12, 2021</study_first_submitted>
  <study_first_submitted_qc>March 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gingival Recession</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

